Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

ACTME Recruiting

2024-516125-31-02 Metastatic Melanoma 9 2024-12-18
Randomized phase 2 study of Valproic acid combinEd with rechallenge anti-EGFR based regimen regimens in pretreated patients with RAS/BRAF wi… Recruiting

2024-514420-16-00 RAS/BRAF wild-type metastatic colorectal cancer 4 2024-12-18
PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATION Recruiting

2024-519286-21-00 MALIGNANT PLEURAL MESOTHELIOMA PATIENTS 5 2024-12-17
Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressin… Recruiting

2024-515624-36-00 Refractary or relapse non-Hodgkin T CD30+ lymphoma. 7 2024-12-17
A clinical study of sacituzumab tirumotecan (sac-TMT) in people with bladder cancer (MK-2870-027) Recruiting

2024-514983-23-01 Intermediate-risk Non-muscle Invasive Bladder Cancer 9 2024-12-16
A First-in-Human clinical trial assessing safety of ES2B-C001 with or without Montanide in patients with HER2 expressing metastatic breast c… Recruiting

2024-516333-12-00 HER2 positive patients under HER2 maintenance therapy ( 1 2024-12-16
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants with Head … Recruiting

2023-508418-40-00 Head and Neck Squamous Cell Carcinoma 9 2024-12-16
ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trial Recruiting

2024-511711-21-00 Stage III non-small cell lung cancer 6 2024-12-16
Iodine Contrasts Effectiveness and Safety in Contrast Enhanced Mammography and breast magnetic resonance imaging. Recruiting

2023-507644-37-00 Breast cancer 5 2024-12-13
Partial or total removal of the pancreas and transplantation of the patient's own islet cells in patients with pancreatic cancer and a high … Recruiting

2023-507773-17-00 Patients with perampullary carcinoma and a high-risk pr 4 2024-12-11
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting

2023-508724-35-00 Patients with pMMR/MSS metastatic adenocarcinoma of the 4 2024-12-10
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subject… Recruiting

2024-513860-25-00 Ovarian Neoplasms 9 2024-12-10
Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in … Recruiting

2023-504925-38-00 patients with hormone receptor (HR)-positive, HER2-nega 4 2024-12-10
[177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with prostate cancer and biochemical but not radio-morphological local recurre… Recruiting

2024-519348-34-00 prostate carcinoma 4 2024-12-09
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting

2024-516839-27-00 BRCA wild-type advanced ovarian, fallopian tube and pri 4 2024-12-09
A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha … Recruiting

2024-516109-21-00 Polycythaemia Vera (PV) 5 2024-12-09
CRISPR-TIL for metastatic melanoma Recruiting

2023-510417-25-01 Advanced or metastatic melanoma 1 2024-12-06
A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therap… Recruiting

2024-512053-24-00 recurrent/metastatic (R/M) head and neck squamous cell 4 2024-12-05
Clinical trial of patritumab deruxtecan in people with gastrointestinal cancers Recruiting

2024-512442-41-00 Colorectal Carcinoma, Biliary Tract Carcinoma, Hepatoce 9 2024-12-03
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Metastatic HER2-positive breast cancer 5 2024-12-03
A study to test long-term treatment with brigimadlin in people with solid tumours who took part in a previous study with this medicine Recruiting

2024-514177-21-00 Solid tumours 4 2024-12-02
Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastoma Recruiting

2023-509673-22-00 Neuroblastoma 9 2024-12-02
Prospective phase IIb study to evaluate the efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic can… Recruiting

2024-519067-17-00 Locally Advanced Pancreatic Cancer 4 2024-12-02
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01